Scancell AIM:SCLP
- Founded
- 1996 · Oxford, England
- Incorporated
- United Kingdom
- Chief executive
- Phillip L'Huillier
- Employees
- 60
- Reports in
- GBP
- Companies House
- 06564638
Clinical-stage immuno-oncology company developing cancer vaccines and antibody therapies from its Moditope and ImmunoBody platforms, with lead programmes in melanoma showing promising clinical data alongside checkpoint inhibitors. Founded from University of Nottingham research; pre-revenue and reliant on partnering or fundraising.
Read straight from the annual reports
9.5p at close on 2 Oct 2026 · 11 reported years, 2015–2025
| Line | FY201504/15 | FY201604/16 | FY201704/17 | FY201804/18 | FY201904/19 | FY202004/20 | FY202104/21 | FY202204/22 | FY202304/23 | FY202404/24 | FY202504/25 | FY2026unreported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | |||||
| Gross profit | — | — | — | — | — | — | — | |||||
| Operating profit | ||||||||||||
| Net finance cost | vs 1.6 | later 1.8 | ||||||||||
| Profit before tax | later (6.3) | |||||||||||
| Tax charge | ||||||||||||
| Profit for the year | later (4.6) | |||||||||||
| EBITDA | ||||||||||||
| Basic EPS | ||||||||||||
| Diluted EPS | ||||||||||||
| Dividend per share | — | — | — | — | — | — | — | — | — |
GBP millions, negatives in brackets. Per-share lines in pence, share counts in millions. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.
4 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Genmab collaboration option/licence exercise fees (non-recurring)
£4.7 million ($6 million) of licence revenue recognised in FY2025 (2024: nil) following Genmab's exercise of its option under the second collaboration agreement (SC2811)
page 39R&D expenditure increase
R&D expenditure increased by £1.8 million to £14.7 million (2024: £12.9 million) due to SCOPE/ModiFY trial enrolment and iSCIB1+ manufacturing scale-up
page 12Lower administrative costs
Administrative expenditure decreased by £0.6 million to £4.8 million (2024: £5.4 million) due to lower professional fees and recruitment costs
page 13iSCIB1+ has been selected for further development, expanding the potential addressable population to 80% of late-stage melanoma patients; regulatory and partnering discussions accelerated, with a randomised Phase 2/3 study on the path to registration anticipated to begin in 2026
page 5GlyMab Therapeutics Limited incorporated in June 2025 as a wholly owned subsidiary to hold and develop the early-stage GlyMab antibody pipeline (two candidates already licensed to and being developed by Genmab)
page 50Auditor RSM UK Audit LLP gave an unqualified true-and-fair opinion, not modified in respect of going concern, but drew attention to a material uncertainty: the Group's two-year cash flow forecast to April 2027 indicates it could operate with cash currently held only until August 2026 (less than 12 months from approval), reliant on inherently uncertain future revenue from new/existing collaboration agreements or additional shareholder/investor funding. Key audit matters were (1) going concern and (2) accounting for the substantial modification of convertible loan notes. Group materiality was £749,000; audit scope covered 100% of expenses, total assets and loss before tax
page 25- Business strategy may change due to social/demographic factors, global inflation, competitor progress, competitive environment changes, key personnel changes or unforeseen eventsp.14
- Future funding requirements and success of partnerships: the Group requires further funding (licensing, debt, equity, or partial business sale) to develop and commercialise its programmes; no guarantee such financing will be secured on favourable terms; material uncertainty relating to going concernp.14
- Technology and products: as a clinical-stage biopharmaceutical company, pipeline products are early-stage with no guarantee they will meet clinical endpoints or gain regulatory approval; safety issues may halt trialsp.14
- Product development timelines may suffer significant delays from patient recruitment or manufacturing/supply issues, requiring further financingp.14
Read from C001141-AR-2025-ch.
10 annual reports read, FY2016 to FY2025
Open a year to see what its report said. Every line in it carries the page it was read from.
Sources: Companies House (10)
FY2026Next report expected 3 Nov 2026